Breast Cancer Clinical Trial
Official title:
Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD009, A Humanized B7-H3 x CD3 Dual-Affinity Re-Targeting (DART) Protein in Patients With Unresectable or Metastatic B7-H3-Expressing Neoplasms
Verified date | February 2022 |
Source | MacroGenics |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to evaluate the safety of MGD009 when given to patients with B7-H3-expressing tumors. The study will also evaluate what is the highest dose of MGD009 that can be given safely. Assessments will be done to see how the drug acts in the body (pharmacokinetics (PK), pharmacodynamics (PD) and to evaluate potential anti-tumor activity of MGD009.
Status | Terminated |
Enrollment | 67 |
Est. completion date | November 25, 2019 |
Est. primary completion date | November 25, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Histologically and/or cytologically proven unresectable locally advanced or metastatic tumors that express B7-H3 on the membrane or vasculature. The requirement for previous systemic therapy may be waived if a person was intolerant of standard front-line therapy - Dose escalation phase prior systemic treatment requirements: - pleural mesothelioma, pancreatic cancer: 1-3 prior treatments - urothelial, SCHNN, prostate, soft tissue sarcoma, prostate cancer, TNBC, ccRCC, NSCLC: 1-5 prior treatments - ovarian cancer: 2-4 prior treatments - colon cancer: 2-4 prior treatments - cutaneous melanoma: at least 1 prior treatment (including immunotherapy). - Patients with prior immune checkpoint inhibitors must have related toxicities reduced to Grade 0, 1, or baseline - Measurable disease per RECIST 1.1 criteria - Easter Cooperative Oncology Group (ECOG) performance status 0 or 1 - Acceptable laboratory parameters and adequate organ reserve. Exclusion Criteria: - Patients with central nervous system (CNS) involvement must have been treated, be asymptomatic, do not exhibit progression of CNS metastases on MRI or CT within 28 days, and do not have concurrent leptomeningeal disease or cord compression. - Clinically significant pulmonary compromise within 28 days of first dose, including pneumonia, pneumonitis, requirement for supplemental oxygen). use to maintain adequate oxygenation, or pleural effusion sufficient to warrant pleurocentesis or any history of = Grade 3 drug induced or radiation pneumonitis. - History of autoimmune disease with certain exceptions such as vitiligo, resolved childhood atopic dermatitis, psoriasis not requiring systemic therapy within the past 2 years, patients with history of Hashimoto's or Grave's disease that are now euthyroid clinically and by lab testing - History of clinically-significant cardiovascular disease, or cardiac arrhythmias, including atrial fibrillation at screening or day of treatment - History of clinically-significant gastrointestinal (GI) disease; GI perforation within 1 year; GI bleeding or acute pancreatitis within 3 months; or diverticulitis within 4 weeks of first study drug administration - Active viral, bacterial, or systemic fungal infection requiring parenteral treatment within 7 days of first study drug administration - Known history of hepatitis B or C infection or known positive test for hepatitis B surface antigen or core antigen, or hepatitis C polymerase chain reaction (PCR) - Known positive testing for human immunodeficiency virus or history of acquired immune deficiency syndrome - History of allogeneic bone marrow, stem cell, or solid organ transplant - Treatment with systemic cancer therapy or investigational therapy within 3 weeks of first study drug administration; radiation within 2 weeks; corticosteroids (greater than or equal to 10 mg prednisone or equivalent per day) or other immune suppressive drugs within 2 weeks of first study drug administration - Trauma or major surgery within 4 weeks of first study drug administration - Known hypersensitivity to recombinant proteins, polysorbate 80, or any excipient contained in the drug or vehicle formulation for MGD009 |
Country | Name | City | State |
---|---|---|---|
Australia | Chris O'Brien Lifehouse | Camperdown | New South Wales |
Australia | Saint Vincent's Hospital Sydney | Darlinghurst | New South Wales |
Australia | Austin Health | Heidelberg | Victoria |
Australia | Linear Clinical Research | Nedlands | Western Australia |
Australia | Princess Alexandra Hospital | Woolloongabba | Queensland |
Canada | Princess Margaret Cancer Centre | Toronto | Ontario |
United States | Dana Farber Cancer Institute | Boston | Massachusetts |
United States | Massachusetts General Hospital | Boston | Massachusetts |
United States | Mary Crowley Cancer Research Center | Dallas | Texas |
United States | Virginia Cancer Specialists | Fairfax | Virginia |
United States | Carolina BioOncology Institute | Huntersville | North Carolina |
United States | UCLA | Los Angeles | California |
United States | Henry-Joyce Cancer Center | Nashville | Tennessee |
United States | Columbia University Medical Center | New York | New York |
United States | New York University | New York | New York |
United States | Stanford University School of Medicine | Palo Alto | California |
United States | Penn Presbyterian Medical Center | Philadelphia | Pennsylvania |
United States | South Texas Accelerated Research Therapeutics, LLC | San Antonio | Texas |
United States | University of California - San Francisco | San Francisco | California |
United States | Georgetown University | Washington | District of Columbia |
Lead Sponsor | Collaborator |
---|---|
MacroGenics |
United States, Australia, Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of participants with adverse events | adverse events, serious adverse events | 28 days after last dose of study drug | |
Secondary | Peak plasma concentration | PK of MGD009 | 8 days | |
Secondary | Number of participants that develop anti-drug antibodies | Proportion of patients who develop anti-MGD0009 antibodies, immunogenicity | first dose through 28 days after last dose of study drug | |
Secondary | Change in tumor volume | Anti-tumor activity of MGD009 using both conventional RECIST 1.1 and immune-related RECIST criteria. | Weeks 6, 15, 24, 33, 42, 51, 60, 69, 78, 87, 96, 105 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A |